Merck takes options to KalVista's plasma kallikrein inhibitors for DME; option period expires
- Controlled Release
- Site Specific
- Drug Delivery
- R+D and Marketing-Licensing
- Includes Equity
- Includes Royalty or Profit Split Information
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.